Humira Takes Nearly 20% Of Enbrel Share; Abbott Eyes Psoriasis Market Next
Executive Summary
Abbott sees psoriasis as the next large market opportunity for Humira after rheumatoid arthritis, Immunology General Manager Tim Walbert said during Abbott's R&D Day in New York May 29
You may also be interested in...
Kaletra Scripts Outpace Sales; Abbott Expects 10% Sales Growth
Prescriptions for Abbott's protease inhibitor Kaletra are outpacing the product's sales growth
Kaletra Scripts Outpace Sales; Abbott Expects 10% Sales Growth
Prescriptions for Abbott's protease inhibitor Kaletra are outpacing the product's sales growth
Humira Managed Care Coverage At 95%; Abbott Raises Sales Forecast
Abbott's Humira is being reimbursed by 95% of managed care organizations three months after the launch of the tumor necrosis factor inhibitor for rheumatoid arthritis